您当前所在的位置:首页 > 产品中心 > 产品信息
Tiagabine_分子结构_CAS_115103-54-3)
点击图片或这里关闭

Tiagabine

产品号 DB00906 公司名称 DrugBank
CAS号 115103-54-3 公司网站 http://www.ualberta.ca/
分子式 C20H25NO2S2 电 话 (780) 492-3111
分子量 375.548 传 真
纯 度 电子邮件 david.wishart@ualberta.ca
保 存 Chembase数据库ID: 782

产品价格信息

请登录

产品别名

标题
Tiagabine
IUPAC标准名
(3R)-1-[4,4-bis(3-methylthiophen-2-yl)but-3-en-1-yl]piperidine-3-carboxylic acid
IUPAC传统名
tiagabine
商标名
Gabitril
别名
Tiagabina [INN-Spanish]
Tiagabinum [INN-Latin]

产品登记号

CAS号 115103-54-3
PubChem CID 60648
PubChem SID 46505560

产品性质

疏水性(logP) 2.6

产品详细信息

详细说明 (English)
Item Information
Drug Groups approved
Description Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
Indication For the treatment of partial seizures
Pharmacology Tiagabine is used primarily as an anticonvulsant for the adjunctive treatment of epilepsy. The precise mechanism by which Tiagabine exerts its antiseizure effect is unknown, although it is believed to be related to its ability to enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter in the central nervous system. Tiagabine binds to recognition sites associated with the GABA uptake carrier. It is thought that, by this action, Tiagabine blocks GABA uptake into presynaptic neurons, permitting more GABA to be available for receptor binding on the surfaces of post-synaptic cells.
Toxicity mptoms most often accompanying tiagabine overdose, alone or in combination with other drugs, have included: seizures including status epilepticus in patients with and without underlying seizure disorders, nonconvulsive status epilepticus, coma, ataxia, confusion, somnolence, drowsiness, impaired speech, agitation, lethargy, myoclonus, spike wave stupor, tremors, disorientation, vomiting, hostility, and temporary paralysis. Respiratory depression was seen in a number of patients, including children, in the context of seizures.
Affected Organisms
Humans and other mammals
Biotransformation Tiagabine is likely metabolized primarily by the 3A isoform subfamily of hepatic cytochrome P450.
Absorption Tiagabine is nearly completely absorbed (>95%).
Half Life 7-9 hours
Protein Binding 96%
Elimination Approximately 2% of an oral dose of tiagabine is excreted unchanged, with 25% and 63% of the remaining dose excreted into the urine and feces, respectively, primarily as metabolites.
Clearance * 109 mL/min [Healthy subjects]
External Links
Wikipedia
RxList
Drugs.com

参考文献